

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM591361

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	CHANGE OF NAME		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BioTime, Inc.		08/09/2019	Corporation:
RECEIVING PARTY DATA			
Name:	Lineage Cell Therapeutics, Inc.		
Street Address:	2173 Salk Avenue, Suite 200		
City:	Carlsbad		
State/Country:	CALIFORNIA		
Postal Code:	92008		
Entity Type:	Corporation: CALIFORNIA		
PROPERTY NUMBERS Total: 14			
Property Type	Number	Word Mark	
Registration Number:	3875742	EXTRALINK	
Registration Number:	3875741	GELIN-S	
Registration Number:	3927432	GLYCOSIL	
Registration Number:	3875740	HEPRASIL	
Registration Number:	1964271	HEXTEND	
Serial Number:	87440298	HYCLUDE	
Serial Number:	77850361	HYSTEM	
Serial Number:	86963568	ITR	
Serial Number:	87440330	PREMVIA	
Registration Number:	4358280	PURESTEM	
Registration Number:	4542126	PURESTEM	
Serial Number:	87440341	REGLYDE	
Serial Number:	87440350	RENELON	
Serial Number:	85594569	RENEVIA	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2126926704		

CH \$365.00 3875742

Email: kwon@mintz.com
Correspondent Name: Karen Won
Address Line 1: One Financial Center
Address Line 4: Boston, MASSACHUSETTS 02111

ATTORNEY DOCKET NUMBER: 058125-400

NAME OF SUBMITTER: Karen Won

SIGNATURE: /Karen Won/

DATE SIGNED: 08/10/2020

Total Attachments: 1

source=Certificate of Ownership#page1.tif

A0831802

15/6/30/2019

CERTIFICATE OF OWNERSHIP

FILED
Secretary of State
State of California

LBO

100 AUG 09 2019

NETO:

Brian M. Culley and Chase C. Leavitt certify that:

1. They are the Chief Executive Officer and Secretary, respectively, of BioTime, Inc. a California corporation (the "Corporation").
2. The Corporation owns all of the outstanding shares of Lineage Cell Therapeutics, Inc., a California corporation (the "Merger Sub").
3. The board of directors of the Corporation duly adopted the following resolutions:


RESOLVED, that the Corporation merge Lineage Cell Therapeutics, Inc., its wholly owned subsidiary corporation, into itself and assume all of its liabilities and obligations pursuant to California Corporations Code Section 1110.

RESOLVED, that Article One of the Corporation's Restated Articles of Incorporation, as amended, shall be amended in its entirety to read as follows:


"ONE: The name of this corporation is Lineage Cell Therapeutics, Inc."

We further declare under penalty of perjury under the laws of the State of California that the matters in this certificate are true and correct of our own knowledge.

Date: August 9, 2019



Brian M. Culley
Chief Executive Officer



Chase C. Leavitt
Secretary



TRADEMARK